Genialis’ Post

🔔 WCLC 2023 -- Initial results from the Dato-Dxd phase Ib trial were presented recently at the World Conference on Lung Cancer (WCLC) 2023. Dato-Dxd is a specifically engineered TROP2-directed DXd ADC being jointly developed by AstraZeneca and Daiichi Sankyo.  TROPION-Lung04 Phase Ib trial showed that Dato-DXd in combination with Imfinzi (durvalumab), an anti-PD-L1 therapy, with or without carboplatin demonstrated encouraging responses and no new safety signals in patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. In previously untreated patients, Dato-DXd plus Infinzi with or without chemotherpy demonstrated ORR of 77% and 50% and DCR of 92% and 93%, respectively. 🔹 DDXCELL provides one-stop cell development service and related cell products to meet needs of ADC research. 👉 Click the link to know products: https://www.ddxcell.cn/ #antibodydiscovery #antibodytherapeutics #celllinedevelopment #cancertreatment  #antibodies #drugdiscovery #adc #solidtumors

Interesting discussion at The Cancer Drug Development Forum (CDDF) workshop regarding access to molecular diagnostics and the waste of healthcare resources and patients' lives by not implementing the right biomarkers. For instance, not identifying oncogene-addicted #NSCLC tumours (both in metastatic and early settings) and instead treating all patients with immune-checkpoint inhibitors, or not screening for #RAS G12 in metastatic colorectal cancer before prescribing trifluridine/tipiracil, or not following the workup for cancer of unknown primary (#CUP)…. Increased transparency regarding testing can highlight challenges at the national level and provide solutions. Thanks to Jaap Verweij, Warnyta Minnaard, Peter Keeling, Ademi Santiago-Walker, Rosa Giuliani, Hyunmin Park & Caroline Marissal / Missie Tumor Onbekend

In this Review, Dr Shitara et al. discuss the biological role of claudin 18.2 in gastric mucosa and in cancer, and clinical development of zolbetuximab, the first agent targeting claudin 18.2, which has demonstrated a significant improvement in survival in phase III trials as well as other claudin 18.2-targeted therapies.

In the phase 2 CAPRI trial, patients with recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR) deficient high-grade serous ovarian cancer (HGSOC) who clinically benefited from PARPi before progression, were treated with ceralasertib (ATR inhibitor) and olaparib (PARP inhibitor) combination and showed an ORR of 50% (95% confidence interval, 0.15-0.72). ATR inhibition re-sensitizes PARPi-resistant cells to PARP inhibition and has an apparent synergistic effect with PARP inhibition. Reported grade 3/4 toxicities were 38%: anemia (15%), thrombocytopenia (23%), and neutropenia (8%). The combination was tolerable and showed activity in patients who progressed with PARPi given as the penultimate regimen. (Ref: Wethington SL, et al. Clin Cancer Res. August 1, 2023) #oncologyresearch #clinicalresearch #clinicaldevelopment https://lnkd.in/ddWiBvMR

🔍 Choosing the right test can be a game-changer in cancer detection. Here's why you should consider Avantect over traditional biomarkers for pancreatic cancer: ✅ Higher Accuracy: Avantect boasts superior sensitivity and specificity, meaning fewer false alarms (false positives) and missed cases (false negatives) than with CA 19-9. ✅ Early Detection: CA 19-9 and CEA are primarily used for monitoring pancreatic cancer rather than early detection. In contrast, Avantect is specifically designed to identify specific genetic markers that can indicate the presence of cancer even in its nascent phase, thereby enhancing the chances of timely intervention.  ✅ Enhanced Clarity: Move past ambiguous results that can obscure the path to appropriate clinical management. Avantect delivers precise insights, enabling more confident and informed clinical decisions. 👉Visit our website to learn more about Avantect and how to start offering the test in your practice: https://www.avantect.com/ #pancreaticcancer #earlydetection

#Merck & Co Inc (NYSE:MRK) and #Eisai announced Friday that their therapeutic combination targeting endometrial cancer as a first-line treatment failed to meaningfully slow the progression of the disease or improve overall survival during a late-stage trial. The Phase 3 LEAP-001 trial evaluated Merck’s anti-PD-1 therapy Keytruda and Eisai’s orally available multiple receptor tyrosine kinase inhibitor Lenvima as a first-line treatment in patients with endometrial cancer, a disease where cancer cells form in the lining of the uterus. The therapeutic combination is already approved in the United States, European Union, Japan, and other countries for the treatment of certain types of advanced endometrial carcinoma following prior systemic therapy.  More at #Proactive #ProactiveInvestors #NYSE #MRK http://ow.ly/iiwX105533P

🔬 #Proteomics in #ClinicalOncology: Three weeks ago, we hosted an evening showcase in Paris – 'Next-Gen Proteomics for Advancing Translational and Clinical Oncology' at the Paris Saclay Cancer Cluster (PSCC). Today, we're happy to announce that the recordings are now available on our website. Don't miss out on Sandra Martínez Martín from Peptomyc discussing the "Biomarker Discovery Programme of OMO-103, a First-in-modality MYC Inhibitor". Despite the challenges associated with targeting the MYC oncoproteins, Omomyc has shown promising results in preclinical models, suggesting its potential therapeutic utility across various solid tumor types. One of the challenges of using therapeutic miniproteins is the development of a PK assay for accurate measurement of the drug within the patient tumor samples. In this presentation, Sandra explains how the de novo TrueSignature® LC-MS/MS proteomic assay was developed and characterized, targeting Omomyc and its use in normal routine of clinical trials for its accurate quantification in tumor biopsies. Join us to delve into the future of proteomics in oncology! 🌐👨🔬 👉 Watch the recording here: https://lnkd.in/eqSJG5By #Oncology #ClinicalResearch #DrugDiscovery #DrugDevelopment #Biomarkers

Nuvectis Pharma announces encouraging preliminary data from the NXP800 phase 1b clinical trial in platinum-resistant ARID1a-mutated ovarian cancer. There is a 33% response rate and 100% disease control rate in patients evaluated for efficacy.  Heat shock transcription factor 1 (HSF1) is critical for tumorigenesis and progression, and is implicated in multiple solid tumors. NXP800 is a potent, clinical stage inhibitor of the HSF1 pathway. The compound activates GCN2 kinase, that phosphorylates the eIF2α and later encodes the ATF4 transcription regulator, resulting in cancer cell death. NXP800 previously gets Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian cancer. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/gJjrRdZz   #ovarian #cancer #OC #Tumor #HSF1 #ISR #GCN2 #eIF2 #Buildingblocks

#ACROHighlights [Featured Product] 🚀 Accelerate your antibody drug and ADC development with HER-2 recombinant proteins! Hengrui Medicine has launched a phase III clinical trial of the ADC drug SHR-A1811. 🌟 The purpose is to compare its therapeutic effect with trastuzumab (T-DM1) in HER-2 positive early breast cancer. 🎯 SHR-A1811, a HER-2-targeted antibody conjugate drug, takes the fight against cancer. 🌟 It binds to and endocytoses HER-2-expressing tumor cells, releases the toxin through protease cleavage, and induces cell cycle arrest, leading to tumor cell apoptosis. 💥 Supercharge your research and unlock new possibilities in cancer treatment. Reach out to us to get high-quality HER-2 Recombinant Proteins! 🔗https://lnkd.in/gqnaZpgA #HER2 #ADC #antibodydrugs #cancerresearch

Freiburg/Oxford: Alithea Bio is thrilled to announce a strategic collaboration with Exogene, co-funded by the German ZIM and Innovate UK, combining our expertise to spearhead #innovations in #T-cell receptor therapy, specifically for cancer treatment.     With Alithea Bio’s focus on #massspectrometry analysis of #HLA-presented #peptides, Alithea Bio holds the largest database of HLA peptide mass spectrometric data, comprising 1.4 million unique peptides identified in 4.160 samples from healthy organs and tumors. In tandem with Exogene, we aim to expand this unique resource to identify novel #targets suitable for #TCR therapy.     This collaboration seamlessly integrates Exogene's advanced AI-driven #T-cell receptor discovery methods with Alithea Bio's expertise in #HLA-peptidomics, streamlining the development of highly specific and effective #cancer therapies. Together, Alithea Bio and Exogene are poised to revolutionize cancer treatment, marking a significant leap forward in facilitating #safe and #effective #Tcell #receptor therapy.     #precisionmedicine #immunopeptidomics #immunotherapy #cancertreatment #tcr